News & Updates
Filter by Specialty:
Navitoclax–ruxolitinib combo doubles spleen response rates in myelofibrosis
In untreated myelofibrosis, using navitoclax in combination with ruxolitinib appears to result in a twofold increase in the number of patients experiencing spleen volume shrinkage, regardless of prognosis, according to updated data from the phase III TRANSFORM-1 trial.
Navitoclax–ruxolitinib combo doubles spleen response rates in myelofibrosis
17 Aug 2024
AI improves physician accuracy in identifying prostate cancer extent
Use of artificial intelligence (AI)-assisted cancer contours helps minimize underestimation of the extent of prostate cancer, thereby improving the physician’s ability in terms of contouring accuracy and negative margin rate, a study has shown.
AI improves physician accuracy in identifying prostate cancer extent
16 Aug 2024
Dabrafenib plus trametinib boasts high pathological response for stage III melanoma
Pathological response rates are high for neoadjuvant dabrafenib plus trametinib among patients with stage III melanoma, but recurrence-free survival (RFS) rates are low, reports a study.
Dabrafenib plus trametinib boasts high pathological response for stage III melanoma
12 Aug 2024
First-line nivolumab-ipilimumab improves life quality, eases symptoms in metastatic CRC
First-line treatment with nivolumab (NIVO) in combination with ipilimumab (IPI) results in better health-related quality of life (HRQOL) and fewer symptoms, when compared with chemotherapy, in patients with centrally confirmed microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), as shown in the CheckMate 8HW study presented at ESMO GI 2024.